Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Alnylam Pharma target lowered to $68 at Needham; Buy (40.63)Needham lowers their ALNY tgt to $68 from $98 after co provided a quarterly corporate update yesterday. Near-term milestones include fitusiran and inclisiran Phase 3 initiations as well as updates from Phase 2 trials of patisiran and inclisiran. Most important milestone this year is Phase 3 patisiran outcome in Sept 2017. Mgmt has recently placed greater emphasis on lead programs in TTR, Hemophilia, and Porphyria, but firm notes RNAi platform and earlier stage programs still hold substantial long-term value. <strong>Reiterate BUY, but they are reducing tgt to reflect lower estimates from removal of ALN-CC5 from model and current risk envm't (25x 2022 EPS 25% annual discount).</strong></td> </tr></table>"